Revusiran

DB16309Investigational

Revusiran is under investigation in clinical trial NCT02319005 (ENDEAVOUR: Phase 3 Multicenter Study of Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC)).

Mechanism: Pharmacologically active on Transthyretin
Curator reviewed
Code names: AD-51547

Resolves to

Compound

UNIIZE6EHM8Z3ACAS1438322-82-7

Targets

P02766TTR

What you can answer from here — as of April 23, 2025

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

4Clinical trialsPhase, status and sponsor resolved per trial

1+ReferenceStructured and connected to the statements they support

Which drugs share a target with Revusiran, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account